Exploring the effects and mechanism of peony pollen in treating benign prostatic hyperplasia

被引:0
|
作者
Mu, Jun [1 ]
Wu, Junsheng [1 ]
Duan, Linrui [1 ]
Yang, Qian [2 ]
Liu, Xiaoting [1 ]
Bai, Huixin [1 ]
Xie, Yanhua [1 ]
Li, Jie [2 ]
Wang, Siwang [1 ]
机构
[1] Northwest Univ, Coll Life Sci, Biomed Key Lab Shaanxi Prov, Xian 710069, Peoples R China
[2] Air Force Med Univ, Sch Pharm, Dept Chinese Mat Med & Nat Med, Xian 710032, Peoples R China
关键词
Peony pollen; Benign prostatic hyperplasia; Network pharmacology; Target prediction; Molecular docking; URINARY-TRACT SYMPTOMS; PLANT FLAVONE; CYCLOOXYGENASE-2; WOGONIN; EPIDEMIOLOGY; SUPPRESSION; CHRYSIN;
D O I
10.1016/j.heliyon.2023.e22212
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Paeonia suffruticosa is widely cultivated globally due to its medicinal and ornamental value. Peony pollen (PP) is commonly used in Chinese folk medicine to make tea to treat benign prostatic hyperplasia (BPH), but its molecular mechanism against BPH is yet to be comprehended. The objective of this research was to experimentally verify the effect of PP in the treatment of BPH and to preliminarily reveal its mechanism of action on BPH using network pharmacology methods. The results revealed that PP could decrease prostate volume and prostate index, serum testos-terone (T), dihydrotestosterone (DHT), and estradiol (E2) levels. Moreover, it could improve prostate tissue structure in BPH model animals as well. Additionally, database searches and disease target matching revealed 81 compounds in PP. Of these, 3, 7, 8, 2 '-tetrahydroxyflavone, Chrysin, Wogonin, Limocitrin, and Sexangularetin were the top five compounds associated with the therapeutic effects of BPH. Furthermore, 177 therapeutic targets for BPH were retrieved from databases of Swiss Target, DisGeNET, Drugbank, Genecards, OMIM, TTD, and Uniprot. In contrast, core targets AKT1, EGFR, IL6, TNF, and VEGFA were obtained by PPI network diagram. Molecular docking also showed that the main efficacy components and potential core targets in PP had good binding capacity. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomics (KEGG) analysis established that the effect of PP in BPH therapy was mainly through regulating the expression levels of protein kinase B on phosphatidylinositol 3-kinase and phosphatidylinositol 3-kinase-protein kinase B pathways. Additionally, Western blot experiments also exhibited a significant elevation in the activated PI3K and AKT proteins in the model (Mod) group relative to the control (Con) group, and the expression of these activated proteins was significantly reduced after PP administration. In summary, this research provides a scientific basis for employing PP to treat BPH, preliminarily reveals its mechanism of action and potential targets, and lays the foundation for further research and development.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Benign prostatic hyperplasia
    Parnham, Arie
    Haq, Ahsanul
    JOURNAL OF CLINICAL UROLOGY, 2013, 6 (01) : 24 - 31
  • [32] Benign Prostatic Hyperplasia
    Kim, Choung Soo
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2007, 50 (07): : 626 - 636
  • [33] Prostatic artery embolization for benign prostatic hyperplasia: a review
    Young, Shamar
    Golzarian, Jafar
    CURRENT OPINION IN UROLOGY, 2018, 28 (03) : 284 - 287
  • [34] Silodosin in the treatment of benign prostatic hyperplasia
    Rossi, Maxime
    Roumeguere, Thierry
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2010, 4 : 291 - 297
  • [35] Pharmacological treatment of benign prostatic hyperplasia
    Oelke, M.
    Kuczyk, M. A.
    Herrmann, T. R. W.
    UROLOGE, 2009, 48 (11): : 1365 - 1375
  • [36] Botulinum neurotoxin A for benign prostatic hyperplasia
    Oeconomou, Athanassios
    Madersbacher, Helmut
    CURRENT OPINION IN UROLOGY, 2010, 20 (01) : 28 - 36
  • [37] Endocrine control of benign prostatic hyperplasia
    La Vignera, S.
    Condorelli, R. A.
    Russo, G. I.
    Morgia, G.
    Calogero, A. E.
    ANDROLOGY, 2016, 4 (03) : 404 - 411
  • [38] Options for the Treatment of Benign Prostatic Hyperplasia
    Plante, Mark
    Wachterman, Jared
    Perrapato, Scott
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2012, 22 (04): : 281 - 287
  • [39] Benign prostatic hyperplasia: A clinical review
    Skinder, Danielle
    Zacharia, Ilana
    Studin, Jillian
    Covino, Jean
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2016, 29 (08): : 19 - 23
  • [40] Pharmacological treatment of benign prostatic hyperplasia
    Oelke, M.
    Martinelli, E.
    UROLOGE, 2016, 55 (01): : 81 - 94